COMMUNIQUÉS West-GlobeNewswire

Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
07/10/2025
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall [...]
Qualigen Therapeutics (NASDAQ: QLGN) Announces Executives, Board of Directors Appointments and Auditor Transition
07/10/2025
Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, [...]
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
07/10/2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil [...]
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
07/10/2025
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended [...]
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
06/10/2025
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced [...]
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
06/10/2025
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION [...]
Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025)
06/10/2025
Sanuwave announces preliminary revenues of $11.4 million to $11.6 million for the third quarter ended September 30, 2025. This represents the highest quarterly revenues in Company history. Q3 2025 revenue increased [...]
Equillium Announces Leadership and Corporate Updates
06/10/2025
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
06/10/2025
Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications at baseline, [...]
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
06/10/2025
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes [...]
Senseonics Announces Preliminary Unaudited Revenue for Third Quarter 2025 and Provides Business Update
06/10/2025
Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, [...]
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
06/10/2025
Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a [...]
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales
06/10/2025
LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on [...]
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
06/10/2025
$5 million tranche received under up to $20 million financing agreement IND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- [...]
Biomea Fusion Announces Proposed Public Offering of Securities
06/10/2025
SAN CARLOS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering [...]

Pages